Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model‐based analysis
Abstract The aim of this study is to compare radiofrequency ablation (RFA) with stereotactic body radiotherapy (SBRT) for hepatocellular carcinomas (HCC) smaller than 3 cm. A Markov cohort model was developed to simulate a cohort of patients aged 60–65 years with small HCCs who had undergone either...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-11-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.893 |
| _version_ | 1811212444866969600 |
|---|---|
| author | Young‐Seok Seo Mi‐Sook Kim Hyung‐Jun Yoo Won Il Jang Eun Kyung Paik Chul Ju Han Byung‐Hee Lee |
| author_facet | Young‐Seok Seo Mi‐Sook Kim Hyung‐Jun Yoo Won Il Jang Eun Kyung Paik Chul Ju Han Byung‐Hee Lee |
| author_sort | Young‐Seok Seo |
| collection | DOAJ |
| description | Abstract The aim of this study is to compare radiofrequency ablation (RFA) with stereotactic body radiotherapy (SBRT) for hepatocellular carcinomas (HCC) smaller than 3 cm. A Markov cohort model was developed to simulate a cohort of patients aged 60–65 years with small HCCs who had undergone either RFA or SBRT and were followed up over their remaining life expectancy. The inclusion criteria were: (1) HCC ≤3 cm in diameter with ≤ 3 nodules; (2) absence of extrahepatic metastasis or portal/hepatic vein invasion; (3) Child‐Pugh Class A or B. Twenty thousand virtual patients were randomly assigned to undergo RFA or SBRT. Predicted life expectancy was 6.452 and 6.371 years in the RFA and SBRT groups, respectively. The probability distributions of the expected overall survival were nearly identical. The 95% confidence intervals were 6.25–6.66 and 6.17–6.58 years for RFA and SBRT, respectively. The difference between RFA and SBRT was insignificant (P = 0.2884). Two‐way sensitivity analysis demonstrated that if the tumor is 2–3 cm, SBRT is the preferred treatment option. Our Markov model has shown that expected overall survival of SBRT is nearly identical to RFA in HCCs smaller than 3 cm, but SBRT may have an advantage for tumors 2 cm and larger. A randomized trial is required to confirm these findings. |
| first_indexed | 2024-04-12T05:29:34Z |
| format | Article |
| id | doaj.art-d929051c61e446538d33edbc3e0f23f1 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-12T05:29:34Z |
| publishDate | 2016-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-d929051c61e446538d33edbc3e0f23f12022-12-22T03:46:08ZengWileyCancer Medicine2045-76342016-11-015113094310110.1002/cam4.893Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model‐based analysisYoung‐Seok Seo0Mi‐Sook Kim1Hyung‐Jun Yoo2Won Il Jang3Eun Kyung Paik4Chul Ju Han5Byung‐Hee Lee6Department of Radiation Oncology Korea Institute of Radiological & Medical Sciences Seoul KoreaDepartment of Radiation Oncology Korea Institute of Radiological & Medical Sciences Seoul KoreaDepartment of Radiation Oncology Korea Institute of Radiological & Medical Sciences Seoul KoreaDepartment of Radiation Oncology Korea Institute of Radiological & Medical Sciences Seoul KoreaDepartment of Radiation Oncology Korea Institute of Radiological & Medical Sciences Seoul KoreaDepartment of Internal Medicine Korea Institute of Radiological & Medical Sciences Seoul KoreaDepartment of Radiology Korea Institute of Radiological & Medical Sciences Seoul KoreaAbstract The aim of this study is to compare radiofrequency ablation (RFA) with stereotactic body radiotherapy (SBRT) for hepatocellular carcinomas (HCC) smaller than 3 cm. A Markov cohort model was developed to simulate a cohort of patients aged 60–65 years with small HCCs who had undergone either RFA or SBRT and were followed up over their remaining life expectancy. The inclusion criteria were: (1) HCC ≤3 cm in diameter with ≤ 3 nodules; (2) absence of extrahepatic metastasis or portal/hepatic vein invasion; (3) Child‐Pugh Class A or B. Twenty thousand virtual patients were randomly assigned to undergo RFA or SBRT. Predicted life expectancy was 6.452 and 6.371 years in the RFA and SBRT groups, respectively. The probability distributions of the expected overall survival were nearly identical. The 95% confidence intervals were 6.25–6.66 and 6.17–6.58 years for RFA and SBRT, respectively. The difference between RFA and SBRT was insignificant (P = 0.2884). Two‐way sensitivity analysis demonstrated that if the tumor is 2–3 cm, SBRT is the preferred treatment option. Our Markov model has shown that expected overall survival of SBRT is nearly identical to RFA in HCCs smaller than 3 cm, but SBRT may have an advantage for tumors 2 cm and larger. A randomized trial is required to confirm these findings.https://doi.org/10.1002/cam4.893Hepatocellular carcinomaMarkovradiofrequency ablationstereotactic |
| spellingShingle | Young‐Seok Seo Mi‐Sook Kim Hyung‐Jun Yoo Won Il Jang Eun Kyung Paik Chul Ju Han Byung‐Hee Lee Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model‐based analysis Cancer Medicine Hepatocellular carcinoma Markov radiofrequency ablation stereotactic |
| title | Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model‐based analysis |
| title_full | Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model‐based analysis |
| title_fullStr | Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model‐based analysis |
| title_full_unstemmed | Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model‐based analysis |
| title_short | Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model‐based analysis |
| title_sort | radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma a markov model based analysis |
| topic | Hepatocellular carcinoma Markov radiofrequency ablation stereotactic |
| url | https://doi.org/10.1002/cam4.893 |
| work_keys_str_mv | AT youngseokseo radiofrequencyablationversusstereotacticbodyradiotherapyforsmallhepatocellularcarcinomaamarkovmodelbasedanalysis AT misookkim radiofrequencyablationversusstereotacticbodyradiotherapyforsmallhepatocellularcarcinomaamarkovmodelbasedanalysis AT hyungjunyoo radiofrequencyablationversusstereotacticbodyradiotherapyforsmallhepatocellularcarcinomaamarkovmodelbasedanalysis AT woniljang radiofrequencyablationversusstereotacticbodyradiotherapyforsmallhepatocellularcarcinomaamarkovmodelbasedanalysis AT eunkyungpaik radiofrequencyablationversusstereotacticbodyradiotherapyforsmallhepatocellularcarcinomaamarkovmodelbasedanalysis AT chuljuhan radiofrequencyablationversusstereotacticbodyradiotherapyforsmallhepatocellularcarcinomaamarkovmodelbasedanalysis AT byungheelee radiofrequencyablationversusstereotacticbodyradiotherapyforsmallhepatocellularcarcinomaamarkovmodelbasedanalysis |